Last reviewed · How we verify

MCT-SR — Competitive Intelligence Brief

MCT-SR (MCT-SR) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nutritional supplement / Lipid formulation. Area: Nutrition / Metabolic support.

phase 3 Nutritional supplement / Lipid formulation Nutrition / Metabolic support Small molecule Live · refreshed every 30 min

Target snapshot

MCT-SR (MCT-SR) — Korea Otsuka Pharmaceutical Co., Ltd.. MCT-SR is a sustained-release formulation of medium-chain triglycerides designed to improve lipid absorption and nutritional support.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
MCT-SR TARGET MCT-SR Korea Otsuka Pharmaceutical Co., Ltd. phase 3 Nutritional supplement / Lipid formulation

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nutritional supplement / Lipid formulation class)

  1. Korea Otsuka Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MCT-SR — Competitive Intelligence Brief. https://druglandscape.com/ci/mct-sr. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: